Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 (KICC COVID-19)
Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Proof-of-Concept Clinical Trial to Evaluate the Efficacy of Ketotifen and Indomethacin for Mild and Moderate COVID-19 in Adults
Sponsor: National University of Singapore
This PHASE3 trial investigates COVID-19 Respiratory Infection and is currently completed. National University of Singapore leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Mar 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Jun 2022 — Mar 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Dec 2021 — Jun 2022 [monthly]
Not Yet Recruiting PHASE3
Phase: PHASE2 → PHASE3
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National University of Singapore
- Sen-Jam Pharmaceutical
For direct contact, visit the study record on ClinicalTrials.gov .